Replimune Group Stock Performance
| REPL Stock | USD 7.38 0.40 5.73% |
The company holds a Beta of 0.57, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Replimune's returns are expected to increase less than the market. However, during the bear market, the loss of holding Replimune is expected to be smaller as well. At this point, Replimune Group has a negative expected return of -0.18%. Please make sure to check Replimune's treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Replimune Group performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Replimune Group has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest uncertain performance, the Stock's basic indicators remain persistent and the latest mess on Wall Street may also be a sign of long-standing gains for the company institutional investors. ...more
Actual Historical Performance (%)
One Day Return 5.81 | Five Day Return 0.54 | Year To Date Return (17.08) | Ten Year Return (51.32) | All Time Return (51.32) |
1 | Replimune Group GAAP EPS of -0.90 misses by 0.11 | 11/06/2025 |
2 | Disposition of 7248 shares by Xynos Konstantinos of Replimune at 9.1 subject to Rule 16b-3 | 11/17/2025 |
3 | Levi Korsinsky Notifies Replimune Group, Inc. Investors - The National Law Review | 12/01/2025 |
4 | Disposition of 10000 shares by Sushil Patel of Replimune at 11.13 subject to Rule 16b-3 | 12/02/2025 |
5 | Disposition of 3169 shares by Dhingra Kapil of Replimune at 1.75 subject to Rule 16b-3 | 12/09/2025 |
6 | Marshall Wace LLP Cuts Holdings in Replimune Group, Inc. REPL | 12/10/2025 |
7 | Insiders At Replimune Group Sold US766k In Stock, Alluding To Potential Weakness | 12/17/2025 |
8 | Acquisition by Andrew Schwendenman of 10000 shares of Replimune subject to Rule 16b-3 | 12/19/2025 |
9 | Acquisition by Emily Hill of 67500 shares of Replimune at 8.4 subject to Rule 16b-3 | 12/26/2025 |
10 | Disposition of 9154 shares by Emily Hill of Replimune at 5.37 subject to Rule 16b-3 | 12/30/2025 |
11 | Is Replimune Group A Risky Investment - | 01/05/2026 |
12 | Replimune Highlights RP1, RP2 Progress Ahead of JPM Conference - TipRanks | 01/12/2026 |
13 | Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update | 02/03/2026 |
| Begin Period Cash Flow | 76.2 M | |
| Total Cashflows From Investing Activities | -23.8 M |
Replimune | Build AI portfolio with Replimune Stock |
Replimune Relative Risk vs. Return Landscape
If you would invest 850.00 in Replimune Group on November 6, 2025 and sell it today you would lose (112.00) from holding Replimune Group or give up 13.18% of portfolio value over 90 days. Replimune Group is currently does not generate positive expected returns and assumes 3.3332% risk (volatility on return distribution) over the 90 days horizon. In different words, 29% of stocks are less volatile than Replimune, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Replimune Target Price Odds to finish over Current Price
The tendency of Replimune Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 7.38 | 90 days | 7.38 | more than 93.0 |
Based on a normal probability distribution, the odds of Replimune to move above the current price in 90 days from now is more than 93.0 (This Replimune Group probability density function shows the probability of Replimune Stock to fall within a particular range of prices over 90 days) .
Replimune Price Density |
| Price |
Predictive Modules for Replimune
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Replimune Group. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Replimune Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Replimune is not an exception. The market had few large corrections towards the Replimune's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Replimune Group, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Replimune within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.47 | |
β | Beta against Dow Jones | 0.57 | |
σ | Overall volatility | 1.06 | |
Ir | Information ratio | -0.15 |
Replimune Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Replimune for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Replimune Group can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Replimune Group generated a negative expected return over the last 90 days | |
| Replimune Group has high historical volatility and very poor performance | |
| Replimune Group has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (247.3 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Replimune Group currently holds about 395.08 M in cash with (192.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Replimune Group has a poor financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update |
Replimune Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Replimune Stock often depends not only on the future outlook of the current and potential Replimune's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Replimune's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 80.6 M | |
| Cash And Short Term Investments | 483.8 M |
Replimune Fundamentals Growth
Replimune Stock prices reflect investors' perceptions of the future prospects and financial health of Replimune, and Replimune fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Replimune Stock performance.
| Return On Equity | -0.96 | ||||
| Return On Asset | -0.45 | ||||
| Current Valuation | 299.82 M | ||||
| Shares Outstanding | 78.44 M | ||||
| Price To Book | 2.90 X | ||||
| EBITDA | (253.92 M) | ||||
| Net Income | (247.3 M) | ||||
| Cash And Equivalents | 395.08 M | ||||
| Cash Per Share | 8.01 X | ||||
| Total Debt | 76.17 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 19.79 X | ||||
| Book Value Per Share | 3.36 X | ||||
| Cash Flow From Operations | (192.25 M) | ||||
| Earnings Per Share | (3.68) X | ||||
| Market Capitalization | 578.91 M | ||||
| Total Asset | 551.33 M | ||||
| Retained Earnings | (948.58 M) | ||||
| Working Capital | 433.52 M | ||||
About Replimune Performance
By examining Replimune's fundamental ratios, stakeholders can obtain critical insights into Replimune's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Replimune is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.52) | (0.54) | |
| Return On Capital Employed | (0.62) | (0.65) | |
| Return On Assets | (0.52) | (0.54) | |
| Return On Equity | (0.68) | (0.65) |
Things to note about Replimune Group performance evaluation
Checking the ongoing alerts about Replimune for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Replimune Group help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Replimune Group generated a negative expected return over the last 90 days | |
| Replimune Group has high historical volatility and very poor performance | |
| Replimune Group has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (247.3 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Replimune Group currently holds about 395.08 M in cash with (192.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Replimune Group has a poor financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update |
- Analyzing Replimune's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Replimune's stock is overvalued or undervalued compared to its peers.
- Examining Replimune's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Replimune's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Replimune's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Replimune's stock. These opinions can provide insight into Replimune's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. Anticipated expansion of Replimune directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Replimune assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Replimune's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Replimune should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Replimune's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.